Long COVID Less Likely in Fully Vaccinated Individuals: Comparative Analysis
Vaccination with at least two doses substantially decreases the reporting of long COVID symptoms, underscoring the protective effect of vaccination against persistent symptoms following SARS-CoV-2 infection and supporting vaccination efforts to mitigate the long-term consequences of COVID-19.
August 2022
COVID-19 Vaccine Booster Effective Against Omicron Variant: Clinical Confirmation
A study confirms that three doses of the COVID-19 vaccine, including a booster dose, provide effective protection against the Omicron variant, supporting the implementation of booster vaccination strategies to enhance immunity and control the spread of SARS-CoV-2 variants.
August 2022
Differentiating Post-Vaccination Symptoms from Early COVID-19: Clinical Considerations
Clinical differentiation of post-vaccination symptoms from early COVID-19 infection is crucial, as some individuals may experience systemic symptoms following vaccination that overlap with COVID-19 symptoms, necessitating accurate diagnostic evaluation and management.
August 2022
Age-Related Immune Response Profiles for SARS-CoV-2: Implications for Vaccination Strategies
Investigation of age-related variations in the quantity and quality of antibody response against SARS-CoV-2 provides insights into vaccine effectiveness and immunization strategies tailored to different age groups.
June 2022
Safety of Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Children: Insights from Clinical Trials
Inactivated SARS-CoV-2 vaccine (CoronaVac) is well tolerated and induces humoral responses in children, supporting its safety and immunogenicity profile in pediatric populations, with implications for COVID-19 vaccination strategies and public health policies.
March 2022
Sputnik V Vaccine Induces Seroconversion and Neutralizing Capacity: Insights from Argentine Research
Argentine investigation published in Cell Reports Medicine demonstrates that the Sputnik V vaccine induces seroconversion and neutralizing capacity, contributing to the growing body of evidence supporting the safety and efficacy of this COVID-19 vaccine candidate.
March 2022
Persistence of SARS-CoV-2 Antibodies Nine Months after Infection: Insights from Population-Based Studies
Antibody levels remain high nine months after SARS-CoV-2 infection, as evidenced by tests conducted across an Italian city, highlighting the durability of the immune response and informing vaccination strategies and public health measures.
March 2022
Effect of Vaccination on Household Transmission of SARS-CoV-2: Implications for Public Health Strategies
Significant reduction in household transmission of SARS-CoV-2 is observed with one dose of vaccines, underscoring the importance of vaccination in controlling community spread and supporting public health efforts to mitigate the COVID-19 pandemic.
Februery 2022
SARS-CoV-2 Infections: Holistic Approach to Vaccines, Therapeutics, and Diagnostics
Vaccines, therapeutics, and diagnostics for SARS-CoV-2 should not be limited to the spike protein, as other viral components may also serve as viable targets for intervention, supporting a holistic approach to COVID-19 prevention and treatment strategies.
Februery 2022
Interval Between Different Vaccines: Clinical Considerations and Public Health Recommendations
Interim clinical considerations provide guidance on the interval between different vaccines for optimal immunization coverage and public health impact, supporting evidence-based decision-making and vaccine administration strategies.
Februery 2022
